RMD Stock Overview
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$239.99|
|52 Week High||US$301.34|
|52 Week Low||US$189.40|
|1 Month Change||6.43%|
|3 Month Change||21.88%|
|1 Year Change||-12.76%|
|3 Year Change||78.51%|
|5 Year Change||228.44%|
|Change since IPO||35,619.44%|
Recent News & Updates
ResMed Non-GAAP EPS of $1.49 beats by $0.03, revenue of $914.74M beats by $2.22M
ResMed press release (NYSE:RMD): Q4 Non-GAAP EPS of $1.49 beats by $0.03. Revenue of $914.74M (+4.4% Y/Y) beats by $2.22M. Non-GAAP gross margin grew 50 bps to 57.8%, non-GAAP operating profit up 4%. Operating cash flow for the quarter was $79.5 million, reflecting the impact of increases in working capital. During the quarter we paid $61.5 million in dividends.
ResMed acquires digital insomnia therapy company mementor to bolster sleep portfolio
ResMed (NYSE:RMD) acquired Leipzig-based mementor to bolster its sleep portfolio in Germany with a digital solution for insomnia. Financial terms of the transaction, which was completed Aug. 1, were not disclosed by ResMed. Mementor developed and owns a digital insomnia therapy solution called somnio, which is Germany's first and only permanently approved Digital Health Application (DiGA) in the field of sleep medicine and thus eligible for reimbursement in the country, ResMed said in an Aug. 2 press release. ResMed added that somnio is available in Germany via "app on prescription." ResMed noted that the acquisition lays foundation to build its digital sleep medicine portfolio in Germany Mementor will be integrated into ResMed in Germany as a separate business segment, which will be co-led by mementor Co-Founder and CEO Noah Lorenz and Katherina Jekerle, who was previously ResMed Germany's senior marketing director and member of German leadership team.
|RMD||US Medical Equipment||US Market|
Return vs Industry: RMD exceeded the US Medical Equipment industry which returned -19.1% over the past year.
Return vs Market: RMD underperformed the US Market which returned -10.2% over the past year.
|RMD Average Weekly Movement||3.8%|
|Medical Equipment Industry Average Movement||9.4%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: RMD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: RMD's weekly volatility (4%) has been stable over the past year.
About the Company
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
ResMed Fundamentals Summary
|RMD fundamental statistics|
Is RMD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RMD income statement (TTM)|
|Cost of Revenue||US$1.51b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||5.32|
|Net Profit Margin||21.78%|
How did RMD perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Does RMD pay a reliable dividends?See RMD dividend history and benchmarks
|ResMed dividend dates|
|Ex Dividend Date||Aug 17 2022|
|Dividend Pay Date||Sep 22 2022|
|Days until Ex dividend||2 days|
|Days until Dividend pay date||38 days|
Does RMD pay a reliable dividends?See RMD dividend history and benchmarks
Is RMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RMD?
Other financial metrics that can be useful for relative valuation.
|What is RMD's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does RMD's PE Ratio compare to its peers?
|RMD PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
IDXX IDEXX Laboratories
BAX Baxter International
ZBH Zimmer Biomet Holdings
EW Edwards Lifesciences
Price-To-Earnings vs Peers: RMD is good value based on its Price-To-Earnings Ratio (45.1x) compared to the peer average (52.3x).
Price to Earnings Ratio vs Industry
How does RMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Earnings vs Industry: RMD is expensive based on its Price-To-Earnings Ratio (45.1x) compared to the US Medical Equipment industry average (34.4x)
Price to Earnings Ratio vs Fair Ratio
What is RMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||45.1x|
|Fair PE Ratio||34.4x|
Price-To-Earnings vs Fair Ratio: RMD is expensive based on its Price-To-Earnings Ratio (45.1x) compared to the estimated Fair Price-To-Earnings Ratio (34.4x).
Share Price vs Fair Value
What is the Fair Price of RMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RMD ($239.99) is trading above our estimate of fair value ($171.8)
Significantly Below Fair Value: RMD is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is ResMed forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RMD's forecast earnings growth (11.7% per year) is above the savings rate (1.9%).
Earnings vs Market: RMD's earnings (11.7% per year) are forecast to grow slower than the US market (14.5% per year).
High Growth Earnings: RMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: RMD's revenue (7.4% per year) is forecast to grow slower than the US market (7.9% per year).
High Growth Revenue: RMD's revenue (7.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RMD's Return on Equity is forecast to be high in 3 years time (21.8%)
Discover growth companies
How has ResMed performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RMD has high quality earnings.
Growing Profit Margin: RMD's current net profit margins (21.8%) are higher than last year (14.8%).
Past Earnings Growth Analysis
Earnings Trend: RMD's earnings have grown by 16.4% per year over the past 5 years.
Accelerating Growth: RMD's earnings growth over the past year (64.3%) exceeds its 5-year average (16.4% per year).
Earnings vs Industry: RMD earnings growth over the past year (64.3%) exceeded the Medical Equipment industry 2.5%.
Return on Equity
High ROE: RMD's Return on Equity (23.2%) is considered high.
Discover strong past performing companies
How is ResMed's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: RMD's short term assets ($1.9B) exceed its short term liabilities ($689.3M).
Long Term Liabilities: RMD's short term assets ($1.9B) exceed its long term liabilities ($1.0B).
Debt to Equity History and Analysis
Debt Level: RMD's net debt to equity ratio (14.9%) is considered satisfactory.
Reducing Debt: RMD's debt to equity ratio has reduced from 54.6% to 23.1% over the past 5 years.
Debt Coverage: RMD's debt is well covered by operating cash flow (45.3%).
Interest Coverage: RMD's interest payments on its debt are well covered by EBIT (44.8x coverage).
Discover healthy companies
What is ResMed current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: RMD's dividend (0.73%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: RMD's dividend (0.73%) is low compared to the top 25% of dividend payers in the US market (3.95%).
Stability and Growth of Payments
Stable Dividend: RMD is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: RMD is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: RMD is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: RMD is not paying a notable dividend for the US market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mick Farrell (50 yo)
Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chief Executive Officer of ResMed Pty Ltd. Mr. Farrell has been the C...
CEO Compensation Analysis
Compensation vs Market: Mick's total compensation ($USD10.39M) is about average for companies of similar size in the US market ($USD12.88M).
Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.
Experienced Management: RMD's management team is seasoned and experienced (7.7 years average tenure).
Experienced Board: RMD's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ResMed Inc.'s employee growth, exchange listings and data sources
- Name: ResMed Inc.
- Ticker: RMD
- Exchange: NYSE
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$35.141b
- Shares outstanding: 146.42m
- Website: https://www.resmed.com
Number of Employees
- ResMed Inc.
- 9001 Spectrum Center Boulevard
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/14 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.